You are here: Industry Insights > Market News > Laurus Labs receives USFDA approvals for two ANDAs under PEPFAR

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

PVP-K30-----pharma excipients(CAS No.9003-39-8)

Tobramycin

Povidone iodine 20% powder

Povidone iodine 10% powder

SULBACTAM SODIUM STERILE

Food Additives Bulk Sucralose Neotame Advantame Powder

Laurus Labs receives USFDA approvals for two ANDAs under PEPFAR

expresspharmaMay 20, 2020

Tag: Laurus Labs , FDA , ANDA , TLE 400

Favorites

Laurus Labs has received approval from USFDA under President’s Emergency Plan for AIDS Relief (PEPFAR) for two Abbreviated New Drug Application (ANDAs) TLE400 (Tenofovir/ Lamivudine/ Efavirenz – 300/300/400 mg) and TLE600 (Tenofovir/ Lamivudine/ Efavirenz – 300/300/600 mg) tablets.

Laurus Labs is one of the few players in the ARV segment to receive approval for TLE 400 tablets. TLE 400 is one of the most preferred regimens in the ARV first-line treatment. The Company already received WHO Pre-Qualification for TLE 400 (Tenofovir/ Lamivudine/ Efavirenz – 300/300/400 mg).

These approvals enable Laurus Labs to launch both the products in several LMIC markets.

Previous:ERT launches Virtual Visit solutions to keep clinical trials on track during COVID-19

Next:COVID-19 has made effective use of data in clinical development even more critical

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Laurus Labs receives USFDA approvals for two ANDAs under PEPFAR | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Ralcolor GMP Standard Single&Double Steel/Aluminous Cleanroom Door Used for Pharmaceutical Factories

High Quality Standard Natural Citrus Paradisi Extract Grapefruit Extract Natural Grapefruit Seed Ex

Panda Spacer KRT-08

Marya Pharmaceutical GMP Standard Dust Free Cleanroom Turnkey Project with HVAC System

Vecuronium (FDA)

High Efficiency GMP Standard Clean Bench with hepa filter

FDF standard butterfly valve

High standard and safety Human Coagulation Factor VIII without preservatives and antibiotics

LGJ-10 Standard Type Experimental Vacuum Freeze Dryer

Laurus Labs receives USFDA approvals for two ANDAs under PEPFAR

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may likeMore>>

You may like
More>>